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Abstract
Background Implantation of 1,3-bis (2-chloroethyl)-1-
nitrosourea (BCNU) wafer for malignant glioma is not
recommended in the case of surgical opening of the
ventricular system during microsurgical tumor resection
because the wafer material may dislocate from the resection
cavity into the ventricular system and cause obstructive
hydrocephalus. TachoSil is an adhesive collagen fleece
used in different surgical disciplines that provides an air-
and liquid-tight seal closing communications between the
ventricular system and the resection cavity after tumor
removal.
Methods Occlusion of ventricular defects with TachoSil
after microsurgical glioma resection was performed in two
patients with newly diagnosed and seven patients with
recurrent malignant glioma prior to BCNU wafer implan-
tation into the resection cavity. Early postoperative cranial
computed tomography (CCT)/MRI and follow-up MRI at
3 months’ intervals were performed with a median follow-
up of 10.4 months.
Results The collagen fleece was identified as a linear
structure hypodense/hypointense to white matter on post-
operative CT/MRI separating the resection cavity from the
ventricular lumen in all cases. In no case did early CCT/
MRI or follow-up MRI reveal wafer material within the
ventricular system. In no case did signs of obstructive
hydrocephalus occur.
Conclusion Sealing of the ventricular system using a
fibrinogen-coated collagen fleece effectively separates the
resection cavity from the ventricular system and allows
implantation of BCNU wafers into the resection cavity. No
morphological evidence for wafer material dislocation into
the ventricular system or obstruction of CSF pathways was
found in nine patients who received 41 follow-up MRI over
10.4 months of follow-up.
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Introduction
Surgical opening of the ventricular system frequently
occurs during the resection of brain tumors located near
the ventricles and is usually well tolerated [6]. Therefore, a
need to close such openings rarely occurs. In terms of
alteration of the pattern of dissemination along the
ependyma and occurrence of tumor dissemination along
the CSF pathways by surgical entry of the ventricular
system during glioma resection, the literature remains
controversial [5]. Whether surgical occlusion of ventricular
openings in the setting of glioma or metastasis surgery
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systematically studied.
However, opening ofthe ventricleslimitsthe use of1,3-bis
(2-chloroethyl)-1-nitrosourea (BCNU) wafer implantation
into the resection cavity for local chemotherapy of malignant
gliomas[19]. BCNU wafer implantation is not recommended
in such situations because the wafer material may dislocate
into the ventricular system and cause acute occlusive
hydrocephalus [4]. Furthermore, high concentrations of
BCNU at the implantation site in direct communication with
the ventricular system may cause self-limiting ventriculitis
associated with a transient hydrocephalus [8]. Because three
clinical phase III trials have demonstrated a survival benefit
for patients implanted with BNCU wafers for both newly
diagnosed malignant glioma [21–23] and recurrent malig-
nant gliomas [3] and several recent reports have now
indicated a safe integration of BCNU wafer treatment into
multimodal treatment strategies with promising preliminary
survival data [1, 2, 12, 13, 15], we have considered
occlusion of larger surgical ventricular openings prior to
wafer implantation using an adhesive collagen fleece
(TachoSil®, Nycomed GmbH, Linz, Austria).
An important property of TachoSil® is to activate the
coagulation cascade by recapitulating the final steps of
physiological bloodclottinginorder tosealthe corresponding
tissue it is applied to. TachoSil® consists of an equine-derived
collagen type I matrix covered with human fibrinogen and
thrombin. In contact with fluid, TachoSil® adheres to the
surface of a wound by thrombin-mediated transformation
of fibrin into fibrin monomer. Fibrin monomers sponta-
neously polymerize into a fibrin clot, which cross-links
for stabilization mediated by endogenous factor XIII
[18]. Coagulation occurs within the collagen matrix and
the wound within 5 min, which leads to conglutination of
the collagen matrix and the wound surface, resulting in an
air- and liquid-tight seal [18]. The adhesive matrix resists
tension force and, because of its elasticity, adapts the
movements of the substrate. The latter has been demon-
s t r a t e di ne x p e r i m e n t a ll u n gs u r g e r ya n db yt h eu s eo f
TachoSil® in occlusion of air leaks after lobectomy in lung
tissue [10, 11]. TachoSil® absorbs within 12 weeks by
phagocytosis and fibrinolysis and is replaced by endoge-
nous granulation tissue. This collagen fleece has been
widely used in vascular, lung, hepatic, urological, and
gynecological surgeries [18].
Neurosurgical applications of TachoSil® (earlier mar-
keted under the name TachoComb®) have mainly focused
on the repair of dural defects [14, 17]. We have used
TachoSil® in a prospective case collection study of nine
patients for occlusion of surgical openings of the ventricular
system during surgery for malignant gliomas scheduled for
implantation of BCNU wafers into the tumor resection
cavity. Postoperative imaging demonstrated occlusion of
the ventricular openings and no evidence of dislocation of
wafer material into the ventricular system over a median
follow-up of 10.4 months. In no case did postoperative
imaging revealed a hydrocephalus, and in no case did
clinical signs suggest a complication associated with the
CSF pathways.
Methods
Patients and surgical procedure
From August 2005 to July 2010, 19 patients with newly
diagnosed malignant gliomas and 24 patients treated for
recurrent malignant gliomas at our institution were treated
by microsurgical tumor resection followed by implantation
of BCNU wafers. In nine patients (21%), the location of
tumors required wide opening of the ventricles to allow
gross total resection of tumors, resulting in fenestrations of
the ventricular system larger than 10 mm. The diameter of
BCNU wafers measures 14 mm. Because eroding wafers
decrease in size and the geometry of resection cavities
frequently requires implantation of wafer fragments, open-
ings of the ventricular system larger than 10 mm were not
considered safe for wafer implantation. All patients gave
written consent to the surgical procedure, including tumor
resection with opening of the ventricular system followed
by occlusion using a collagen fleece and local BCNU wafer
implantation. In one patient with newly diagnosed and eight
patients with recurrent malignant gliomas, surgical open-
ings of the ventricular system were closed using TachoSil®
(Table 1). The collagen fleece was cut to cover the entire
defect and overlap with the adjacent resection edge by at
least 5 mm. The fleece was applied wet and pressed to the
tissue surface using dry surgical cotton for 1 min; then, the
cotton was removed and the resection cavity was kept dry
for 5 min. The resection cavity was rinsed to ensure
hemostasis and the BCNU wafers implanted (Fig. 1). The
dura and wound were closed and perioperative antibiotics
and dexamethasone schedule was given adhering to a
protocol specifically designed to avoid wound healing
abnormalities and to minimize other risks associated with
local chemotherapy using BCNU wafers [7].
Postoperative imaging and follow-up
As routine protocol at our institution 4 h postoperatively, all
patients received a cranial computed tomography (CCT) to
rule out early perioperative complications. Within 48 h, an
MRI scan was obtained and prior to discharge a CCT or
MRI performed at postoperative day 10 according to a
follow-up protocol developed for patients receiving BCNU
wafer chemotherapy. After discharge, patients were sched-
534 Acta Neurochir (2011) 153:533–539uled for visits at the neurosurgical–neurooncology outpa-
tient clinic at postoperative days 14, 21, 42, and 65 for
wound inspection, evaluation of blood parameters, and
clinical status. Three months postoperatively, a follow-up
MRI was done and repeated at 3-month intervals [7].
Results
Intraoperative pliability and versatility
After contact with irrigation fluid, the collagen fleece
became pliable and easily adapted to the surface contour
of the resection cavity. After modeling and gently pressing
the fleece against the tissue with dry surgical cotton, in all
cases, the fleece firmly adhered to the wound. In no case
was air or CSF leakage from the ventricular system into the
resection cavity observed for the remaining time of
hemostasis and wafer implantation until dural closure.
Postoperative imaging
Four-hour postoperative CT scans in all patients showed
residual air and the BCNU wafers appearing as hyperdense
linear structures within the resection cavity. The collagen
fleece could be identified as a linear structure hypodense to
white matter separating the resection cavity from the
ventricular lumen (Fig. 2a). On a 24-h postoperative MRI
(Fig. 2b, c), as previously described, the BCNU wafers in
all patients appeared as hypointense structures; after
Fig. 1 Occlusion of surgical opening of the ventricular system after
resection of a recurrent malignant glioma (patient 7) using a
fibrinogen-coated collagen fleece (TachoSil®) prior to implantation
of BCNU wafers (Gliadel). a Opening of the right frontal horn of the
ventricle. b Occlusion of the ventricular fenestration by TachoSil®. c
Implantation of seven BCNU-containing wafers (Gliadel)
Table 1 Characteristics of patients and OAS after surgery with wafer implantation
Gender,
age
KPS prior/after surgery and
BCNU wafer Implantation
Diagnoses No. of implanted
BCNU wafers
Follow-up/survival after surgery
with wafer implantation (months)
OAS
(months)
Adverse events
associated with CSF
pathways
M, 66 80/70 Newly
diagnosed
GBM
8 23.9 23.9 –
F, 59 90/90 Recurrent
GBM
7 10.4 17.0 –
F, 51
a 90/90 Recurrent
Astro III
7 21.5 30.8 –
M, 51 60/60 Recurrent
GBM
7 2.0 20.8 –
F, 59 60/60 Recurrent
GBM
7 3.4 25.2 –
M, 57
a 60/60 Recurrent
GBM
8 24.6 31.4 –
M, 41
a 70/70 Recurrent
Astro III
7 4.7 44.4 –
F, 38
a 100/100 Recurrent
GBM
8 3.8 39.6 –
M, 31
a 80/80 Recurrent
GBM
8 16.9 20.8 –
aAlive at the time of data analysis
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ment of the wafer structure or adjacent brain was observed
[8, 9, 16]. The collagen fleece appeared hypointense on T1-
weighted MRI between the ventricular lumen and the
resection cavity. In all cases, tri-planar MRI demonstrated
a separation of the resection cavity from the ventricular
system by the collagen fleece. In no case did early CCT or
MRI reveal wafer material within the ventricular system or
signs of obstructive hydrocephalus (Table 2). In no case
was contrast enhancement of the ependyma as a sign of
aseptic ventriculitis observed [8].
On 3 months’ follow-up MRI, the resection cavity after
BCNU wafer implantation typically showed a ring-shaped
contrast enhancement around the resection cavity with
varying degrees of perifocal edema [7]. This phenomenon
has been well documented in the literature. Contrast
enhancement will usually resolve within 3–6 months, but
may persist for up to 10 months. Wafer remnants can be
identified in the resection cavity on MRI for 4–6 months [9,
16]. Expectedly, this appearance of the resection cavity and
dynamics of contrast enhancement were also confirmed in
this study. On 3 months’ postoperative MRI, the collagen
fleece appears replaced by a granulation tissue with spongy
structure, hypointense on T1- and hyperintense on T2-
weighted MRI (Fig. 3c, d).
None of the 41 follow-up MRIs in nine patients followed
for a median of 10.4 months (range, 2–24.6 months)
revealed signs of wafer material dislocated to the ventric-
ular system at any time point.
Clinical course and outcome
The postoperative recovery of all patients was uneventful,
and the median postoperative hospitalization was 11.5 days.
Fig. 2 Appearance of collagen fleece (TachoSil®) and BCNU wafers
(Gliadel) on postoperative imaging in a case of recurrent malignant
glioma. a Four-hour postoperative CCT: The collagen fleece is
occluding the entire ventricular defect; BCNU wafers are detectable
within the resection cavity. b Postoperative (24-h) MRI T2w:
Hypointense collagen fleece separates the tumor cavity from the
ventricle. c T1w+GD, there is no enhancement of the wafer structure
or the adjacent brain and the collagen fleece appears hypointense;
otherwise, there were no signs of enhancement of the ependyma
Table 2 Postoperative CCT and MRI results
Appearance of collagen fleece Appearance of wafer material
in resection cavity
Foreign material within the
ventricular system
Hydrocephalus
4-h postoperative
CCT
Hypodense to white matter Linear hyperdense structure None of 9 cases None of 9
cases
24- to 72-h
postoperative
MRI
T1w±GD and T2w hypointense Hypointense None of 8 cases
a None of
8 cases
a
3 months’
postoperative
MRI
T1w hypointense remnants, T2
hyperintense, spongy configuration,
no contrast enhancement
T2w hypointense remnants None of 7 cases
b None of 7
cases
b
aNo early postoperative MRI available for analysis in one patient
bThree-month follow-up not reached for two patients
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without necessity of surgical intervention. No patient
developed clinical signs of acute or subacute hydrocephalus
in the perioperative phase; no patient required treatment for
hydrocephalus during the entire follow-up. For seven
patients, follow-up MRI demonstrated signs of tumor
progression, and at the time of data summary, four patients
had died. Clinical deterioration occurred in five patients and
in all cases was associated with MRI-documented progres-
sion of tumors. In no case was MRI-documented tumor
progression associated with morphological signs of com-
munication of the resection cavity with the previously
collagen fleece-sealed ventricular system, and in no case
was dislocation of wafer material from the cavity or
necrotic tumor focus observed despite mass effect (compare
Fig. 3c, d).
Discussion
While generally surgical entry into the ventricular system
does not require reconstruction, an open communication
of the resection site and the ventricles may pose a
significant problem for strategies that rely on the direct
delivery of pharmaceuticals to the resection cavity. The
distribution of compounds delivered by direct infusion
into the resection cavity or through catheters placed
into tissue surrounding the resection site as used in
convection-enhanced delivery may be difficult, if not
impossible, to predict in the case of open communication
of the resection site with the ventricular system. For local
chemotherapy using biodegradable wafers, communica-
tion of the implantation site and the ventricular system
has been an exclusion criterion in the pivotal phase III
trials because of concerns that the wafer material may
dislocate into the ventricular system, causing obstruction
of the CSF pathways [3, 21, 23]. However, it was
suggested that openings of the ventricle significantly
smaller than the diameter of a wafer do not preclude the
use of BCNU wafers [20]. Gallego et al. [4] reported three
cases of fatal hydrocephalus in patients treated with
BCNU wafers after wide opening of the ventricular system
1–5 months after implantation. In all three cases, the
wafers had been fixed to the wall of the resection site
using fibrin glue, but the ventricular system itself
remained open. Imaging in all three cases failed to directly
visualize dislocation of the wafer material causing
obstruction of the CSF pathways, but because the stability
Fig. 3 Occlusion of ventricular
opening with collagen fleece
(TachoSil®) followed by BCNU
wafer (Gliadel) implantation in a
case of multifocal glioblastoma.
Reoperationwasdoneforarapidly
progressive left frontal focus under
chemotherapy. Twenty-four-hour
MRI (a) and 10-day postoperative
CCT (b) demonstrating the hypo-
dense collagen fleece separating
the resection cavity from the
ventricular system in which the
wafer material can be identified. c
Three-month postoperative MRI
T1w+GD. Ring-shaped contrast
enhancement of the resection
cavity was suspected as early
local progression, causing mass
effect. Residues of collagen fleece
appear hypointense, occluding the
left frontal horn of the ventricle. d
Three-month postoperative T2w
MRI. Spongy tissue replaces the
collagen fleece (yellow arrow).
Wafer remnants can be identified
in the resection cavity. Despite
mass effect of the cystic cavity,
there are no signs of communica-
tion through the ventricular defect
occluded with the collagen fleece
3 months after surgery
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it can prevent wafers from dislocation over the course of
wafer biodegradation. MRI imaging has well demonstrated
that wafer remnants may be found within the resection
cavity 4–6 months after implantation, suggesting that any
strategy not permanently closing large communications
between the resection site and the ventricular system may
be dangerous in this setting. However, dislocation of
wafers may not be the only mechanism resulting in
hydrocephalus. We have recently reported a case of
transient hydrocephalus in a patient who received BCNU
wafer implantation into a resection cavity with a sub-wafer
diameter communication to the ventricular system [8].
B a s e do nt h eo b s e r v a t i o no ft h et r a n s i e n tn a t u r eo ft h e
hydrocephalus manifesting 10 days post-implantation,
resolving spontaneously by postoperative day 20, we have
suggested that high concentrations of BCNU entering the
ventricular system may cause an aseptic ventriculitis and
subsequent self-limiting hydrocephalus [8]. In standard
implantation settings with resection cavities communicat-
ing with the subarachnoid space, a similar phenomenon is
frequently observed. Aseptic meningitis with clinical signs
of meningitis, CSF pleocytosis in the absence of an
infectious agent, and a self-limiting clinical course
occurred in approximately 5% of patients treated with
BCNU wafers and has been suggested to be a result of
high intrathecal BCNU concentrations [13]. These obser-
vations strongly argue for a robust and permanent
occlusion of communications of the resection site with
the ventricular system if local chemotherapy is considered.
Conclusion
Surgical entry of the ventricular system during resection of
malignant brain tumors has limited implantation of BCNU
wafers for local chemotherapy. Postoperative imaging
showed that sealing of the ventricular system using a
fibrinogen-coated collagen fleece separates the resection
cavity from the ventricular system with no evidence of
wafer dislocation into the ventricular system on long-term
follow-up MRI. The implantation of the collagen fleece was
well tolerated in this small series of patients with no
evidence of implant-related adverse events or adverse
events associated with the CSF pathways. Based on our
experience of occlusion of nine ventricular openings larger
than 10 mm in nine patients followed over a mean follow-
up of 10.4 months, we conclude that occlusion of these
defects using TachoSil is safe. Early postoperative imaging
and routine 3-month MRI follow-up in a total of 41 MRI
studies have not revealed any evidence of early or late
wafer dislocation, obstructive hydrocephalus, or any evi-
dence of transient or permanent hydrocephalus in patients
where the ventricular defect had been entirely covered with
the collagen fleece.
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Comment
Bock et al. report their experience about the implantation of BCNU
wafers after high-grade glioma removal when a communication larger
than 10 mm is finally detected between surgical and ventricular cavities.
They implanted BCNU wafers on the cavity walls after covering the
defect with an adhesive collagen fleece (TachoSil). No post-implantation
cases of obstructive hydrocephalus occurred. No other complications
related to the CSF pathway were recorded. The issue is remarkable and
theauthors’effortisappreciableconsideringtheworldwideuseofBCNU
wafers and the frequent wide opening of ventricles required to achieve
gross total tumor removal. In our experience, a piece of gelatine sponge
fixedwithfibringluethencoveredwithoxidizedcellulosewassuitableto
manage ventricular defects smaller than 10 mm in diameter (Della Puppa
A et al, World Neurosurgery, in press). The 10-mm cutoff was defined
because the BCNU wafer’s diameter is actually 14 mm. Patients affected
by large ventricular defects, as in the presented series, have been not
considered up to now appropriate for BCNU wafer implantation. This
condition was considered a critical issue by the manufacturer and also in
the relevant literature (Attenello FJ et al., Ann Surg Oncol, 2008). In this
sense, the authors’ experience could even extend in future inclusion
criteriafor BCNUwaferimplantation.Finally,inorder toachieveabetter
management of patients treated with carmustine wafers, we would like to
emphasize the importance of additional short-term follow-up MRI
imaging after surgery (Della Puppa A et al., Acta Neurochir, 2010).
Domenico d’Avella
Alessandro Della Puppa
Padova, Italy
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